Myovant Sciences rejects $2.5bn takeover bid from Sumitomo Pharma

Retrieved on: 2022-10-13 10:35:17

Tags for this article:

Click the tags to see associated articles and topics

Myovant Sciences rejects $2.5bn takeover bid from Sumitomo Pharma. View article details on hiswai:

Excerpt

By GlobalData Healthcare ... Orgovyx (relugolix) and Myfembree, for the treatment of advanced prostate cancer and women's health respectively.

Article found on: www.pharmaceutical-technology.com